Global Blood Therapeutics, Inc.
HISTONE METHYLTRANSFERASE INHIBITORS
Last updated:
Abstract:
The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Status:
Application
Type:
Utility
Filling date:
4 Nov 2020
Issue date:
15 Apr 2021